Title of Invention	A MEDICAMENT FOR CONGESTIVE HEART FAILURE COMPRISING PRETREATED AUTOLOGOUS BLOOD
Abstract	The present invention relates to a medicament for congestive heart failure (CHF) in a human patient suffering there from comprising an aliquot of modified blood of the patient,prepared by subjecting the aliquot of the patient's blood ex vivo with stressors comprising untraviolet light and an oxidative enviroment.

Full Text

on its own or in combination with other therapies, such as nitrate therapy, P- blockers, ACE inhibitors, AT receptor blocking agents, aldosterone antagonists, calcium channel blocking agents, TNF blocking agents, suppressors of production of TNF-a, and/or other more routine treatment measures such as sodium and fluid restriction, diuretics, digitalis, etc. Specific drugs known to suppress TNF-a production include pentoxifylline, amrinone, adenosine, thalidomide, TNF converting enzyme (TACE) inhibitors and dexamethasone. Specific TNF blocking agents include monoclonal antibodies and etanercept. Accordingly the present invention provides a medicament for congestive heart failure (CHF) in a human patient suffering there from comprising an aliquot of modified blood of the patient, prepared by subjecting the aliquot of the patient's blood ex vivo with stressors comprising ultraviolet light and an oxidative environment. In another aspect, the present invention provides a combination treatment for CHF in a human patient suffering therefrom, the combination treatment including the administration to the patient of an aliquot of the patient's own blood which has been treated ex vivo with one or more stressors selected from an oxidative environment, thermal stress and electromagnetic emission, and a treatment selected from the group consisting' of nitrates, p-blockers ACE inhibitors, AT receptor blocking agents, aldosterone antagonists, calcium channel blocking agents, TNF blocking agents, suppressors of production of TNF-a, sodium and fluid restriction, diuretics and digitalis. BRIEF DESCRIPTION OF THE DRAWINGS The invention is now described, by way of example only, with reference to the accompanying drawings in which: WE CLAIM: 1. A medicament for congestive heart failure (CHF) in a human patient suffering there from comprising an aliquot of modified blood of the patient, prepared by subjecting the aliquot of the patient's blood ex vivo with stressors comprising ultraviolet light and an oxidative environment. 2. The medicament according to claim 1, wherein the oxidative environment comprises application of an oxidizing agent to the aliquot. 3. The medicament according to claim 2, wherein the oxidizing agent contains ozone gas, and the ozone gas is introduced into the blood aliquot in an amount which does not give rise to excessive levels of cell damage. 4. The medicament according to claim 2 or claim 3, wherein the oxidizing agent comprises a mixture of ozone gas and medical grade oxygen, the ozone gas being contained in the mixture in a concentration of upto 300 |!g/ml. 5. The medicament according to claim 4, wherein the ozone gas is contained in the mixture in a concentration of up to 30 |ig/ml. 6. The medicament according to claim 5, wherein the ozone gas is contained in the mixture in a concentration of from 13.5 (ig/ml to 15.5 |^g/ml. 7. The medicament according to claim 4, claim 5 or claim 6, wherein the mixture is applied to the aliquot at a flow rate of up to 0.33 litres/min. 8. The medicament according to claim 7, wherein the mixture is applied to the aliquot at a flow rate of from 0.21 litres/min to 0.27 litres/min. 9. The medicament according to any preceding claim, wherein the ultraviolet light used in treating the blood aliquot comprises ultraviolet light having one or more UV-C band wavelengths. 10. The medicament according to any preceding claim, wherein the temperature to which the aliquot is cooled or heated during the treating of the blood aliquot is a temperature such that at least part of the aliquot is in the range of from -5°C to 55°C. 11. The medicament according to any preceding claim, wherein the mean temperature of the blood in the aliquot during the treating step is in the range of from 37°C to 55°C. 12. The medicament according to any preceding claim, wherein the mean temperature in the blood in the aliquot during the treating step is in the range of from 0°C to 36.5°C. 13. The medicament according to claim 12, wherein said mean temperature of the blood in the aliquot is in the range of from 10°C to 30°C. 14. The medicament according to claim 11, wherein said temperature is 42.5 ± 1°C. 15. The medicament according to any preceding claim, wherein the volume of the aliquot is from 0.1 to 400 ml. 16. The medicament according to claim 15, wherein the volume of the aliquot is from 0.1 to 100ml. 17. The medicament according to claim 15, wherein the volume of the aliquot is from 5 to 15ml. 18. The medicament according to any preceding claim, wherein aliquot is treated with the stressors for a period of up to 60 minutes. 19. The medicament according to claim 18, wherein the aliquot is treated with the stressors for a period of from 2-5 minutes. 20. The medicament according to any preceding claim, wherein the aliquot is treated with ultraviolet light and an oxidative environment simultaneously. 21. A medicament for congestive heart failure (CHF) in a human patient suffering therefrom, comprising, a combination of an aliquot of the patient's own blood which has been subjected ex vivo with one or more stressors selected from an oxidative environment, thermal stress and electromagnetic emission; and a pharmaceutical agent selected from the group consisting of nitrates, p-blockers, ACE inhibitors, AT receptor blocking agents, aldosterone antagonists, calcium channel blocking agents, TNF blocking agents, suppressors of production of TNF-a, sodium and fluid restriction, diuretics and digitalis. 22. The medicament according to claim 21,wherein the pharmaceutical agent is a suppressor of TNF-a selected from the group comprising pentoxifyline, TACE inhiobitors, amrinone, adenosine, thalidomide and dexamethasone. 23. The medicament according to claim 21 on claim 22 wherein the stressors comprise an oxidative environment and ultraviolet light, applied simultaneously to the blood aliquot ex vivo. 24. The medicament according to claim 23 wherein the oxidative environment comprises a mixture of medical grade oxygen and ozone bubbled through the blood aliquot, and the ultraviolet light comprises ultraviolet light having one or more UV-C band wavelength, applied simultaneously to the blood aliquot ex vivo whilst the blood in the aliquot has a mean temperature in the range from 37°C to 55°C. 25. A medicament for congestive heart failure substantially as herein described with reference to the accompanying drawings.

Documents:

in-pct-2002-1287-che-abstract.pdf

in-pct-2002-1287-che-claims duplicate.pdf

in-pct-2002-1287-che-claims original.pdf

in-pct-2002-1287-che-correspondance others.pdf

in-pct-2002-1287-che-correspondance po.pdf

in-pct-2002-1287-che-description complete duplicate.pdf

in-pct-2002-1287-che-description complete original.pdf

in-pct-2002-1287-che-drawings.pdf

in-pct-2002-1287-che-form 1.pdf

in-pct-2002-1287-che-form 26.pdf

in-pct-2002-1287-che-form 3.pdf

in-pct-2002-1287-che-form 5.pdf

in-pct-2002-1287-che-other documents.pdf

in-pct-2002-1287-che-pct.pdf